Altimmune $ALT pemvidutide 48-week MASH data: 32.4% achieved combined fibrosis improvement vs 3.2% placebo (EASL 2026)
MASH liver disease patients on Altimmune $ALT pemvidutide were ~10x more likely to achieve combined fibrosis improvement at 48 weeks than placebo: 32.4% on the 1.8 mg dose vs 3.2% placebo. Trial also showed 23.7% triglyceride drop and 7.5% weight loss. EASL 2026 data.
Patients with metabolic dysfunction-associated steatohepatitis (MASH), a severe fatty liver disease affecting millions worldwide, now have new 48-week clinical data from Altimmune $ALT pemvidutide. In the IMPACT Phase 2b trial presented at EASL 2026 on May 28, 32.4% of patients receiving the 1.8 mg dose and 27.8% of patients receiving the 1.2 mg dose achieved both a clinically meaningful reduction in Enhanced Liver Fibrosis score and a 30% or greater reduction in Liver Stiffness Measurement at 48 weeks. The placebo group hit the same combined endpoint in just 3.2% of patients. The trial also reported triglyceride reductions of 23.7%, total cholesterol reductions of 15.4%, weight loss of 7.5%, and about 1% discontinuations for adverse events. Pemvidutide is a balanced glucagon/GLP-1 dual receptor agonist: the glucagon activation acts directly on the liver to reduce fat, inflammation and fibrosis, while the GLP-1 mechanism drives appetite suppression and weight loss. The FDA has already granted Fast Track and Breakthrough Therapy Designations for MASH, and the EASL scientific committee included the abstract in its Best of EASL 2026 selection.